// STATE LEGISLATION TRACKER

Massachusetts H4490 — An Act prohibiting discrimination against 340b drug discount program participants

⚖️ NEUTRAL for peptide users 👤 NONE user impact 📜 Status: Unknown

State: Massachusetts
Bill: H4490
Filed: 2025-09-18
Read the bill: OpenStates →
Last reviewed: 2026-06-21

Plain-English Summary

H4490 appears to target discrimination against participants in the federal 340B drug discount program. Based on the title and listed subject only, it does not appear to regulate compounded peptides, off-label prescribing, telehealth, clinician scope, FDA 503A/503B compounding, controlled substances, or prescription monitoring.

Key Points

No clear impact on compounded peptide availability
No apparent change to off-label prescribing rules
No apparent telehealth or NP/naturopath scope change
Main relevance is 340B drug discount participation
Peptide users should not expect direct access changes

What to Watch For

Note Bill text was not available from the provided source, so analysis is based only on title, subject, and status note.

Note If later text adds pharmacy benefit manager or pharmacy network rules, indirect access effects could become relevant.

✓

Opportunity 340B protections could help covered clinics maintain discounted outpatient drug access, but this is not peptide-specific.

Where the Bill Stands

The provided OpenStates record reports that refetch failed and gives no reliable latest action, so the bill's current position is unknown.

— Ed. Our analysis pulls public bill metadata from OpenStates and is enriched with research-model context. We don't quote bill text we haven't read directly. If this bill matters to your practice or treatment access, read the official source linked above before taking action. We're an educational research directory, not a legal or medical reference.

Bill page generated 2026-06-21 · enriched via codex gpt-5.5
Source: OpenStates v3 API · View official bill · ← back to all laws